How policy, data infrastructure, and AI shape real‑world impact.
A discussion with the ROI of HEOR Working Group representatives.
Key perspectives and insights from leading 340B experts.
Senior leaders from Novo Nordisk, Bayer, Johnson & Johnson, and Takeda discuss how to move RWD from a supporting resource to a genuine strategic asset.
Deep Dive from the World Orphan Drug Congress USA 2026.
Eunice Hankinson (Flatiron Health) discusses use of the VALID Framework to evaluate an LLM-extracted prostate cancer dataset.
